|
A Phase 3 Study of Pembrolizumab in Combination with Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab with or without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) (KEYLYNK-008)
NCT ID : 03976362
Protocol Number : MK-7339-008
Phase : 3
|
Clinical Trials Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Mena
|
|
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (KEYLYNK-006)
NCT ID : 03976323
Protocol Number : MK-7339-006
Phase : 3
|
Clinical Trials Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Mena
|
|
Phase II, Double-Blind, Randomized Trial Of AVOVA-1 (Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens) Vs. Autologous Peripheral Blood Mononuclear Cells (MC) In Patients With Stage III Or IV Epithelial Ovarian, Fallopian Tube Or Primary Peritoneal Carcinoma After Primary Therapy
NCT ID : 02033616
Phase : 2
|
Clinical Trials Gynecologic Oncology
|
Friedman
|
|
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Study of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Rituximab Versus Placebo in Combination With Rituximab in Treatment Naïve Subjects With Follicular Lymphoma (PERSPECTIVE)
NCT ID : 02947347
Phase : 3
|
Clinical Trials Hematology Oncology
|
Mena
|
|
A Phase III Prospective Randomized Trial of Acupuncture for Treatment of Radiation-Induced Xerostomia in Patients With Head and Neck Cancer
NCT ID : 02589938
Phase : 3
|
Brain Tumors & Neuroscience Clinical Trials
|
Mena
|
|
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil (Nuvigil®) To Reduce Cancer-Related Fatigue in Patients With High Grade Glioma
NCT ID : 01781468
Phase : 3
|
Brain Tumors & Neuroscience Clinical Trials
|
Sanghani
|
|
A Randomized Parallel Group Phase III Trial of OSE2101 as 2nd or 3rd Line Compared With Standard Treatment (Docetaxel or Pemetrexed) in HLA-A2 Positive Patients With Locally Advanced (IIIB) Unsuitable for Radiotherapy or Metastatic (IV) Non-Small-Cell Lung Cancer (ATALANTE 1)
NCT ID : 02654587
|
Clinical Trials Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Mena
|
|
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
NCT ID : 02954991
Phase : 2
|
Clinical Trials Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
Mena
|
|
A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
NCT ID : 01872975
|
Breast Surgery and Oncology Clinical Trials
|
Sanghani
|
|
Palbociclib in Hormone Receptive Positive Advanced Breast Cancer: A Prospective Multicenter Non-International Study (POLARIS)
NCT ID : 03280303
|
Breast Surgery and Oncology Clinical Trials
|
Shankar
|
|
A Phase III Trial of With Marizomib in Patients With Newly Diagnosed Glioblastoma
NCT ID : 03345095
Phase : 3
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Pemetrexed for the Treatment of Chordoma
NCT ID : 03955042
Phase : 1
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Clinical Implementation of a Polygenic Risk Score (PRS) for Breast Cancer
NCT ID : 03688204
|
Breast Surgery and Oncology
|
Gordon and Grumley
|
|
Integrating Family Caregiver Support into Cancer Clinical Trials
NCT ID : 03069287
|
Cancer Support
|
Saria
|
|
A Phase 1/2a Study to Evaluate the Safety, Tolerability, and Efficacy of Relatlimab Administered in Combination with Ipilimumab or Ipilimumab Alone in Participants with Unresectable or Metastatic Melanoma Who Have Progressed on Anti-PD-1 Therapy
NCT ID : 03978611
Phase : 1/2a
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905)
NCT ID : 03924895
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
NCT ID : 03924856
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy
NCT ID : 03898180
Protocol Number : MK-7902-011
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
StimRouter™ for Pain Management in Post-stroke Shoulder Pain (PSSP)
NCT ID : 03093935
Protocol Number : STMR – PAIN 002 PSSP
|
Brain Tumors & Neuroscience
|
Langevin
|
|
Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy
NCT ID : 03709888
Protocol Number : JWCI-17-0101
|
Brain Tumors & Neuroscience
|
Kesari
|
|
An Exploratory Study of Caregiver Burden Among Family Caregivers of Patients With Cancer
NCT ID : 03069105
|
Cancer Support
|
Saria
|
|
CancerLife: Patient-Driven Solution in Cancer Care
NCT ID : 03371147
|
Cancer Support
|
Saria
|
|
Allogeneic Human Mesenchymal Stem Cells for Alzheimer’s Disease
NCT ID : 02833792
Protocol Number : STEM105-M-AD
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Overactive Bladder Treatment Using StimRouter Neuromodulation System: A Prospective Randomized Trial
NCT ID : 02873312
Protocol Number : CP-STMR-OAB-002
|
Brain Tumors & Neuroscience
|
Langevin
|
|
Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT ID : 02847559
Protocol Number : NU 16C02
Phase : 11
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Longitudinal Assessment of Tumor Evolution in Patients With Brain Cancer
NCT ID : 03425292
Protocol Number : JWCI-17-0801
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients (STELLAR)
NCT ID : 02796261
Protocol Number : OT-15-001 (20162068)
Phase : 3
|
Brain Tumors & Neuroscience
|
Kesari
|
|
TALAPRO-1: A Phase 2, Open-Label, Response Rate Study of Talazoparib in Men with DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer who Previously Received Taxane-Based Chemotherapy and Progressed on at Least 1 Novel Hormonal Agent (Enzalutamide and/or Abiraterone Acetate/Prednisone)
NCT ID : NCT03148795
Protocol Number : MDV3800-06 (C3441006)
Phase : 2
|
Urology and Urologic Oncology
|
Twardowski
|
|
A Phase 1 Study of AGEN1181, an Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Subjects With Advanced Cancer
NCT ID : NCT03860272
Protocol Number : C-800-01
Phase : 1
|
Breast Surgery and Oncology Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination With Ipilimumab or Nivolumab Monotherapy in Participants With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H)
NCT ID : NCT03668119
Protocol Number : CA209-848
Phase : 2
|
Breast Surgery and Oncology Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies
NCT ID : 03637764
Protocol Number : ACT15377
Phase : 1 and 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Open- Label Trial of Sipuleucel-T Administered to Patients on Active Surveillance for Newly Diagnosed Prostate Cancer
NCT ID : 03686683
Protocol Number : P17-1 (ProVent)
Phase : 3
|
Urology and Urologic Oncology
|
Twardowski
|
|
Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors
NCT ID : 03684785
Protocol Number : AST-008-102
Phase : 1b/2
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Using Virtual Reality (VR) Models for Preoperative Planning
NCT ID : 03334344
Protocol Number : VR Models
|
Urology and Urologic Oncology
|
Linehan
|
|
An Open-label, Nonrandomized, Phase 1 Study to Evaluate the Safety and Pharmacokinetics of Belinostat in Patients with Relapsed/Refractory Solid Tumors or Hematological Malignancies who Have Wild-Type, Heterozygous, and Homozygous UGT1A1*28 Genotypes
NCT ID : 02680795
Protocol Number : SPI-BEL-106
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase I, Open-Label, Multicenter Study Investigating the Tolerability and Efficacy of UV1 Vaccine in First-Line Malignant Melanoma Patients Planned for Treatment with Pembrolizumab
NCT ID : 03538314
Protocol Number : UV1-hTERT-MM-103
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
Phase II Trial of AV-GBM-1 (Autologous Dendritic Cells Loaded with Autologous Tumor Associated Antigens) as Adjunctive Therapy Following Primary Surgery plus Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03400917
Protocol Number : CL-GBM-P01-US
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
ProSTAR: A Phase 1b/2 Study of CPI-1205, a Small Molecule Inhibitor of EZH2, Combined with Enzalutamide or Abiraterone/Prednisone in Patients with Metastatic Castration Resistant Prostate Cancer
NCT ID : 03480646
Protocol Number : 1205-201
Phase : Ib/II
|
Urology and Urologic Oncology
|
Twardowski
|
|
The Efficacy and Safety of UGN-102 as a Chemoablation Agent in Patients With LG NMIBC at Intermediate Risk of Recurrence
NCT ID : 03558503
Protocol Number : TC-BC-12
Phase : 2
|
Urology and Urologic Oncology
|
Linehan
|
|
A Pivotal Randomized Study Assessing Vagus Nerve Stimulation (VNS) During Rehabilitation for Improved Upper Limb Motor Function After Stroke (VNS-REHAB)
NCT ID : 03131960
Protocol Number : MT-St-03
Phase : 3
|
Brain Tumors & Neuroscience
|
Langevin
|
|
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
NCT ID : 03553836
Protocol Number : MK-3475-716
Phase : 3
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
|
A Phase 2, Open-label Study of ABI-009 (nab-Rapamycin) in Bevacizumab-naïve Patients with Recurrent High-grade Glioma and in Patients with Newly Diagnosed Glioblastoma
NCT ID : 03463265
Protocol Number : GBM-007
Phase : 2
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine
NCT ID : 03633110
Protocol Number : GEN-009-101
Phase : 1 and 2
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology Urology and Urologic Oncology
|
Twardowski
|
|
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage IIB or IIIA Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)
NCT ID : 03425643
Protocol Number : MK-3475-671
Phase : IIB or IIIA
|
Melanoma, Skin and Soft Tissue Tumors Minimally Invasive Chest Surgery and Thoracic Surgical Oncology
|
O'Day
|
|
A Single-Center, Open-Label, Randomized, Phase II Study of NovoTTF-200A Alone and Combined with Temozolomide in Patients with Low-Grade Gliomas
NCT ID : 02507232
Protocol Number : JWCI-16-1101 (20162693)
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Phase II Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Subjects with High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Camette-Guerin (BCG) Therapy
NCT ID : 02625961
Protocol Number : MK-3475-057 (20160487)
Phase : II
|
Urology and Urologic Oncology
|
Wilson
|
|
A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer
NCT ID : 02423525
Protocol Number : 1200-229 (20161975)
Phase : I
|
Brain Tumors & Neuroscience
|
Kesari
|
|
A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy
NCT ID : NCT03149003
Protocol Number : BBI-DSP7888-201G
Phase : II
|
Brain Tumors & Neuroscience
|
Kesari
|
|
Recombinant Human Arginase 1 (RhArg1) in Patients with Advanced, Arginine Auxotrophic Solid Tumors: Dose Escalation, Safety And PK/PD
NCT ID : 02285101
Protocol Number : BCT-100-005
Phase : I
|
Melanoma, Skin and Soft Tissue Tumors
|
O'Day
|
